Natural Product (NP) Details
| General Information of the NP (ID: NP5766) | |||||
|---|---|---|---|---|---|
| Name |
Ginsenoside Rh2
|
||||
| Synonyms |
(20S)-ginsenoside Rh2; 20(S)-Ginsenoside Rh2; Ginsenoside-Rh2; 20(S)-Ginsenoside; CHEBI:77147; UNII-0JU44A5KWG; 0JU44A5KWG; (2R,3R,4S,5S,6R)-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; C36H62O8; 20S-Ginsenoside Rh2; 20(S)-Ginsenoside-RH2; (S)Ginsenoside-Rh2; (20R)Ginsenoside Rh2; CHEMBL1783834; DTXSID70999457; 112246-15-8; 67400-17-3; HY-N0605; BDBM50023457; Ginsenoside Rh2, analytical standard; MFCD00800712; s9023; s9036; ZINC72129809; AKOS037514675; CCG-270259; CCG-270261; CS-3835; X1143; C22128; 12,20-Dihydroxydammar-24-en-3-yl hexopyranoside; 214G332; Q-100827; Q27146703; 3beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,20beta-diol; beta-D-Glucopyranoside, (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl
Click to Show/Hide
|
||||
| Species Origin | Panax ginseng ... | Click to Show/Hide | |||
| Panax ginseng | |||||
| Disease | Prostate cancer [ICD-11: 2C82] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.981
MDCK Permeability
-5.146
PAMPA
+++
HIA
- - -
Distribution
VDss
-0.5
PPB
78.4%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
-
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
- -
Excretion
CLplasma
2.363
T1/2
1.735
Toxicity
DILI
-
Rat Oral Acute Toxicity
- - -
FDAMDD
- - -
Respiratory
- -
Human Hepatotoxicity
++
Ototoxicity
+++
Drug-induced Nephrotoxicity
+++
Drug-induced Neurotoxicity
- - -
Hematotoxicity
+
Genotoxicity
- -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C36H62O8
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)O)C
|
||||
| InChI |
1S/C36H62O8/c1-20(2)10-9-14-36(8,42)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(32(3,4)24(33)12-17-34(25,35)6)44-31-30(41)29(40)28(39)23(19-37)43-31/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1
|
||||
| InChIKey |
CKUVNOCSBYYHIS-IRFFNABBSA-N
|
||||
| CAS Number |
CAS 78214-33-2
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Sodium selenite | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Sodium selenite and G-Rh2 combination have a synergistic effect on cell growth inhibition (57%) compared with sodium selenite (25%) and G-Rh2 alone (28%) after 24 hours of treatment. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Apoptosis mediating surface antigen FAS (FAS) | Molecule Info | [3] | |
| Cellular tumor antigen p53 (TP53) | Molecule Info | [4] | ||
| Estrogen receptor (ESR) | Molecule Info | [5] | ||
| Extracellular signal-regulated kinase 1 (ERK1) | Molecule Info | [5] | ||
| Extracellular signal-regulated kinase 2 (ERK2) | Molecule Info | [5] | ||
| Fatty acid synthase (FASN) | Molecule Info | [3] | ||
| Mothers against decapentaplegic homolog 1 (GAB1) | Molecule Info | [6] | ||
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [7] | ||
| Nucleoporin Nup62 (NUP62) | Molecule Info | [7] | ||
| Vascular endothelial growth factor receptor 2 (KDR) | Molecule Info | [6] | ||
| Zinc finger protein GLIS3 (WDR7) | Molecule Info | [8] | ||
| BioCyc | Fatty acid biosynthesis initiation | Click to Show/Hide | ||
| 2 | Fatty acid elongation -- saturated | |||
| 3 | Palmitate biosynthesis | |||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | cGMP-PKG signaling pathway | |||
| 6 | cAMP signaling pathway | |||
| 7 | Chemokine signaling pathway | |||
| 8 | HIF-1 signaling pathway | |||
| 9 | FoxO signaling pathway | |||
| 10 | Sphingolipid signaling pathway | |||
| 11 | Oocyte meiosis | |||
| 12 | mTOR signaling pathway | |||
| 13 | PI3K-Akt signaling pathway | |||
| 14 | Adrenergic signaling in cardiomyocytes | |||
| 15 | Vascular smooth muscle contraction | |||
| 16 | Dorso-ventral axis formation | |||
| 17 | TGF-beta signaling pathway | |||
| 18 | Axon guidance | |||
| 19 | VEGF signaling pathway | |||
| 20 | Osteoclast differentiation | |||
| 21 | Focal adhesion | |||
| 22 | Adherens junction | |||
| 23 | Gap junction | |||
| 24 | Signaling pathways regulating pluripotency of stem cells | |||
| 25 | Platelet activation | |||
| 26 | Toll-like receptor signaling pathway | |||
| 27 | NOD-like receptor signaling pathway | |||
| 28 | Natural killer cell mediated cytotoxicity | |||
| 29 | T cell receptor signaling pathway | |||
| 30 | B cell receptor signaling pathway | |||
| 31 | Fc epsilon RI signaling pathway | |||
| 32 | Fc gamma R-mediated phagocytosis | |||
| 33 | TNF signaling pathway | |||
| 34 | Circadian entrainment | |||
| 35 | Long-term potentiation | |||
| 36 | Neurotrophin signaling pathway | |||
| 37 | Retrograde endocannabinoid signaling | |||
| 38 | Glutamatergic synapse | |||
| 39 | Cholinergic synapse | |||
| 40 | Serotonergic synapse | |||
| 41 | Long-term depression | |||
| 42 | Regulation of actin cytoskeleton | |||
| 43 | Insulin signaling pathway | |||
| 44 | GnRH signaling pathway | |||
| 45 | Progesterone-mediated oocyte maturation | |||
| 46 | Estrogen signaling pathway | |||
| 47 | Melanogenesis | |||
| 48 | Prolactin signaling pathway | |||
| 49 | Thyroid hormone signaling pathway | |||
| 50 | Oxytocin signaling pathway | |||
| 51 | Type II diabetes mellitus | |||
| 52 | Aldosterone-regulated sodium reabsorption | |||
| 53 | Alzheimer's disease | |||
| 54 | Prion diseases | |||
| 55 | Alcoholism | |||
| 56 | Shigellosis | |||
| 57 | Salmonella infection | |||
| 58 | Pertussis | |||
| 59 | Leishmaniasis | |||
| 60 | Chagas disease (American trypanosomiasis) | |||
| 61 | Toxoplasmosis | |||
| 62 | Tuberculosis | |||
| 63 | Hepatitis C | |||
| 64 | Hepatitis B | |||
| 65 | Influenza A | |||
| 66 | Pathways in cancer | |||
| 67 | Viral carcinogenesis | |||
| 68 | Proteoglycans in cancer | |||
| 69 | Colorectal cancer | |||
| 70 | Renal cell carcinoma | |||
| 71 | Pancreatic cancer | |||
| 72 | Endometrial cancer | |||
| 73 | Glioma | |||
| 74 | Prostate cancer | |||
| 75 | Thyroid cancer | |||
| 76 | Melanoma | |||
| 77 | Bladder cancer | |||
| 78 | Chronic myeloid leukemia | |||
| 79 | Acute myeloid leukemia | |||
| 80 | Non-small cell lung cancer | |||
| 81 | Central carbon metabolism in cancer | |||
| 82 | Choline metabolism in cancer | |||
| 83 | Cell cycle | |||
| 84 | p53 signaling pathway | |||
| 85 | Apoptosis | |||
| 86 | Wnt signaling pathway | |||
| 87 | Amyotrophic lateral sclerosis (ALS) | |||
| 88 | Huntington's disease | |||
| 89 | Measles | |||
| 90 | HTLV-I infection | |||
| 91 | Herpes simplex infection | |||
| 92 | Epstein-Barr virus infection | |||
| 93 | Transcriptional misregulation in cancer | |||
| 94 | MicroRNAs in cancer | |||
| 95 | Basal cell carcinoma | |||
| 96 | Small cell lung cancer | |||
| 97 | Endocrine and other factor-regulated calcium reabsorption | |||
| 98 | Protein processing in endoplasmic reticulum | |||
| 99 | Cytokine-cytokine receptor interaction | |||
| 100 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 101 | Type I diabetes mellitus | |||
| 102 | African trypanosomiasis | |||
| 103 | Autoimmune thyroid disease | |||
| 104 | Allograft rejection | |||
| 105 | Graft-versus-host disease | |||
| 106 | Endocytosis | |||
| 107 | Fatty acid biosynthesis | |||
| 108 | Metabolic pathways | |||
| 109 | Fatty acid metabolism | |||
| 110 | AMPK signaling pathway | |||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| 3 | FSH Signaling Pathway | |||
| 4 | EGFR1 Signaling Pathway | |||
| 5 | RANKL Signaling Pathway | |||
| 6 | IL2 Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Apoptosis signaling pathway | |||
| 4 | B cell activation | |||
| 5 | EGF receptor signaling pathway | |||
| 6 | Endothelin signaling pathway | |||
| 7 | FGF signaling pathway | |||
| 8 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 9 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
| 10 | Integrin signalling pathway | |||
| 11 | Interferon-gamma signaling pathway | |||
| 12 | Interleukin signaling pathway | |||
| 13 | PDGF signaling pathway | |||
| 14 | Parkinson disease | |||
| 15 | TGF-beta signaling pathway | |||
| 16 | T cell activation | |||
| 17 | Toll receptor signaling pathway | |||
| 18 | VEGF signaling pathway | |||
| 19 | Ras Pathway | |||
| 20 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
| 21 | CCKR signaling map ST | |||
| 22 | Huntington disease | |||
| 23 | Wnt signaling pathway | |||
| 24 | p53 pathway | |||
| 25 | P53 pathway feedback loops 1 | |||
| 26 | p53 pathway by glucose deprivation | |||
| 27 | p53 pathway feedback loops 2 | |||
| 28 | FAS signaling pathway | |||
| Pathwhiz Pathway | Fatty Acid Biosynthesis | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| 3 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| 4 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| 5 | Insulin Signalling | |||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
| 2 | Endothelins | |||
| 3 | BCR signaling pathway | |||
| 4 | Signaling events mediated by PRL | |||
| 5 | ErbB4 signaling events | |||
| 6 | GMCSF-mediated signaling events | |||
| 7 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 8 | S1P3 pathway | |||
| 9 | EPHB forward signaling | |||
| 10 | Osteopontin-mediated events | |||
| 11 | S1P4 pathway | |||
| 12 | Presenilin action in Notch and Wnt signaling | |||
| 13 | TRAIL signaling pathway | |||
| 14 | CDC42 signaling events | |||
| 15 | Signaling events regulated by Ret tyrosine kinase | |||
| 16 | Angiopoietin receptor Tie2-mediated signaling | |||
| 17 | S1P1 pathway | |||
| 18 | Regulation of Telomerase | |||
| 19 | Netrin-mediated signaling events | |||
| 20 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 21 | Glucocorticoid receptor regulatory network | |||
| 22 | Arf6 downstream pathway | |||
| 23 | mTOR signaling pathway | |||
| 24 | IL2-mediated signaling events | |||
| 25 | EGF receptor (ErbB1) signaling pathway | |||
| 26 | Ras signaling in the CD4+ TCR pathway | |||
| 27 | Ceramide signaling pathway | |||
| 28 | Integrins in angiogenesis | |||
| 29 | IFN-gamma pathway | |||
| 30 | ErbB1 downstream signaling | |||
| 31 | ATF-2 transcription factor network | |||
| 32 | ErbB2/ErbB3 signaling events | |||
| 33 | ALK1 signaling events | |||
| 34 | PDGFR-beta signaling pathway | |||
| 35 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 36 | Syndecan-1-mediated signaling events | |||
| 37 | Retinoic acid receptors-mediated signaling | |||
| 38 | Nongenotropic Androgen signaling | |||
| 39 | CXCR3-mediated signaling events | |||
| 40 | VEGFR1 specific signals | |||
| 41 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||
| 42 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 43 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 44 | Syndecan-2-mediated signaling events | |||
| 45 | Cellular roles of Anthrax toxin | |||
| 46 | S1P2 pathway | |||
| 47 | Trk receptor signaling mediated by the MAPK pathway | |||
| 48 | Downstream signaling in naï | |||
| 49 | ||||
| 50 | VEGFR3 signaling in lymphatic endothelium | |||
| 51 | Alpha-synuclein signaling | |||
| 52 | FGF signaling pathway | |||
| 53 | Signaling events mediated by HDAC Class III | |||
| 54 | Validated targets of C-MYC transcriptional activation | |||
| 55 | LKB1 signaling events | |||
| 56 | Direct p53 effectors | |||
| 57 | p75(NTR)-mediated signaling | |||
| 58 | AP-1 transcription factor network | |||
| 59 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||
| 60 | Signaling mediated by p38-alpha and p38-beta | |||
| 61 | Aurora A signaling | |||
| 62 | BARD1 signaling events | |||
| 63 | p53 pathway | |||
| 64 | PLK3 signaling events | |||
| 65 | Regulation of nuclear SMAD2/3 signaling | |||
| 66 | Signaling events mediated by HDAC Class II | |||
| 67 | Plasma membrane estrogen receptor signaling | |||
| 68 | FOXM1 transcription factor network | |||
| 69 | Validated nuclear estrogen receptor alpha network | |||
| 70 | FOXA1 transcription factor network | |||
| 71 | p73 transcription factor network | |||
| 72 | FAS (CD95) signaling pathway | |||
| 73 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 74 | Caspase Cascade in Apoptosis | |||
| 75 | Validated transcriptional targets of TAp63 isoforms | |||
| 76 | HIF-2-alpha transcription factor network | |||
| 77 | Beta3 integrin cell surface interactions | |||
| 78 | Signaling events mediated by TCPTP | |||
| 79 | SHP2 signaling | |||
| 80 | VEGF and VEGFR signaling network | |||
| 81 | Notch-mediated HES/HEY network | |||
| 82 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 83 | Class IB PI3K non-lipid kinase events | |||
| 84 | BMP receptor signaling | |||
| 85 | Signaling events mediated by focal adhesion kinase | |||
| Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
| 2 | RAF-independent MAPK1/3 activation | |||
| 3 | ISG15 antiviral mechanism | |||
| 4 | ERK/MAPK targets | |||
| 5 | Regulation of actin dynamics for phagocytic cup formation | |||
| 6 | Oxidative Stress Induced Senescence | |||
| 7 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 8 | Oncogene Induced Senescence | |||
| 9 | FCERI mediated MAPK activation | |||
| 10 | Regulation of HSF1-mediated heat shock response | |||
| 11 | NCAM signaling for neurite out-growth | |||
| 12 | Activation of the AP-1 family of transcription factors | |||
| 13 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 14 | Negative regulation of FGFR1 signaling | |||
| 15 | Negative regulation of FGFR2 signaling | |||
| 16 | Negative regulation of FGFR3 signaling | |||
| 17 | Negative regulation of FGFR4 signaling | |||
| 18 | RHO GTPases Activate WASPs and WAVEs | |||
| 19 | RAF/MAP kinase cascade | |||
| 20 | MAP2K and MAPK activation | |||
| 21 | Negative feedback regulation of MAPK pathway | |||
| 22 | Negative regulation of MAPK pathway | |||
| 23 | Signal attenuation | |||
| 24 | Advanced glycosylation endproduct receptor signaling | |||
| 25 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 26 | Growth hormone receptor signaling | |||
| 27 | Activation of NOXA and translocation to mitochondria | |||
| 28 | Activation of PUMA and translocation to mitochondria | |||
| 29 | Pre-NOTCH Transcription and Translation | |||
| 30 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | |||
| 31 | DNA Damage/Telomere Stress Induced Senescence | |||
| 32 | Autodegradation of the E3 ubiquitin ligase COP1 | |||
| 33 | TP53 Regulates Metabolic Genes | |||
| 34 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| 35 | Stabilization of p53 | |||
| 36 | Factors involved in megakaryocyte development and platelet production | |||
| 37 | Nuclear signaling by ERBB4 | |||
| 38 | Nuclear Receptor transcription pathway | |||
| 39 | FasL/ CD95L signaling | |||
| 40 | Neurophilin interactions with VEGF and VEGFR | |||
| 41 | VEGF binds to VEGFR leading to receptor dimerization | |||
| 42 | Integrin cell surface interactions | |||
| 43 | EPHA-mediated growth cone collapse | |||
| 44 | VEGFA-VEGFR2 Pathway | |||
| 45 | VEGFR2 mediated cell proliferation | |||
| 46 | ChREBP activates metabolic gene expression | |||
| 47 | Activation of gene expression by SREBF (SREBP) | |||
| 48 | Fatty Acyl-CoA Biosynthesis | |||
| 49 | MAPK1 (ERK2) activation | |||
| 50 | Golgi Cisternae Pericentriolar Stack Reorganization | |||
| 51 | Recycling pathway of L1 | |||
| 52 | CREB phosphorylation through the activation of Ras | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| 3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| 4 | Serotonin HTR1 Group and FOS Pathway | |||
| 5 | TCR Signaling Pathway | |||
| 6 | Hypothetical Network for Drug Addiction | |||
| 7 | EPO Receptor Signaling | |||
| 8 | TGF Beta Signaling Pathway | |||
| 9 | Regulation of Actin Cytoskeleton | |||
| 10 | IL-2 Signaling Pathway | |||
| 11 | Insulin Signaling | |||
| 12 | MAPK Cascade | |||
| 13 | IL-4 Signaling Pathway | |||
| 14 | MAPK Signaling Pathway | |||
| 15 | IL-6 signaling pathway | |||
| 16 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 17 | Kit receptor signaling pathway | |||
| 18 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
| 19 | IL-3 Signaling Pathway | |||
| 20 | Cardiac Hypertrophic Response | |||
| 21 | MAP kinase activation in TLR cascade | |||
| 22 | Fc epsilon receptor (FCERI) signaling | |||
| 23 | RAF/MAP kinase cascade | |||
| 24 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 25 | Genes and (Common) Pathways Underlying Drug Addiction | |||
| 26 | Signal Transduction of S1P Receptor | |||
| 27 | PDGF Pathway | |||
| 28 | Alpha 6 Beta 4 signaling pathway | |||
| 29 | Spinal Cord Injury | |||
| 30 | BDNF signaling pathway | |||
| 31 | Integrated Pancreatic Cancer Pathway | |||
| 32 | Oncostatin M Signaling Pathway | |||
| 33 | Corticotropin-releasing hormone | |||
| 34 | Interleukin-11 Signaling Pathway | |||
| 35 | AGE/RAGE pathway | |||
| 36 | TNF alpha Signaling Pathway | |||
| 37 | Prostate Cancer | |||
| 38 | Signaling Pathways in Glioblastoma | |||
| 39 | TSLP Signaling Pathway | |||
| 40 | IL-9 Signaling Pathway | |||
| 41 | IL17 signaling pathway | |||
| 42 | Alzheimers Disease | |||
| 43 | IL-7 Signaling Pathway | |||
| 44 | TWEAK Signaling Pathway | |||
| 45 | FSH signaling pathway | |||
| 46 | Leptin signaling pathway | |||
| 47 | RANKL/RANK Signaling Pathway | |||
| 48 | IL-1 signaling pathway | |||
| 49 | Thrombin signalling through proteinase activated receptors (PARs) | |||
| 50 | Signaling by Insulin receptor | |||
| 51 | Signaling by FGFR | |||
| 52 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
| 53 | L1CAM interactions | |||
| 54 | Advanced glycosylation endproduct receptor signaling | |||
| 55 | Apoptosis Modulation and Signaling | |||
| 56 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 57 | Regulation of toll-like receptor signaling pathway | |||
| 58 | Osteopontin Signaling | |||
| 59 | IL-5 Signaling Pathway | |||
| 60 | DNA Damage Response (only ATM dependent) | |||
| 61 | DNA Damage Response | |||
| 62 | ErbB Signaling Pathway | |||
| 63 | Senescence and Autophagy in Cancer | |||
| 64 | G1 to S cell cycle control | |||
| 65 | Sandbox Pathway | |||
| 66 | Wnt Signaling Pathway and Pluripotency | |||
| 67 | TGF beta Signaling Pathway | |||
| 68 | Copper homeostasis | |||
| 69 | Bladder Cancer | |||
| 70 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
| 71 | Pre-NOTCH Expression and Processing | |||
| 72 | Apoptosis | |||
| 73 | ATM Signaling Pathway | |||
| 74 | Amyotrophic lateral sclerosis (ALS) | |||
| 75 | Retinoblastoma (RB) in Cancer | |||
| 76 | Gastric cancer network 2 | |||
| 77 | Metastatic brain tumor | |||
| 78 | Integrated Breast Cancer Pathway | |||
| 79 | Integrated Cancer pathway | |||
| 80 | Intrinsic Pathway for Apoptosis | |||
| 81 | Factors involved in megakaryocyte development and platelet production | |||
| 82 | Cell Cycle | |||
| 83 | Cell Cycle Checkpoints | |||
| 84 | Folate Metabolism | |||
| 85 | TP53 Network | |||
| 86 | Fluoropyrimidine Activity | |||
| 87 | miRNAs involved in DNA damage response | |||
| 88 | miRNA Regulation of DNA Damage Response | |||
| 89 | AMPK Signaling | |||
| 90 | Estrogen signaling pathway | |||
| 91 | Nuclear Receptors Meta-Pathway | |||
| 92 | Estrogen Receptor Pathway | |||
| 93 | Signaling by ERBB4 | |||
| 94 | JAK/STAT | |||
| 95 | miR-targeted genes in muscle cell - TarBase | |||
| 96 | Nuclear Receptors | |||
| 97 | Oxidative Stress | |||
| 98 | Transcriptional activation by NRF2 | |||
| 99 | NRF2 pathway | |||
| 100 | Aryl Hydrocarbon Receptor Pathway | |||
| 101 | Mesodermal Commitment Pathway | |||
| 102 | Aryl Hydrocarbon Receptor | |||
| 103 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 104 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 105 | Apoptosis Modulation by HSP70 | |||
| 106 | FAS pathway and Stress induction of HSP regulation | |||
| 107 | Adipogenesis | |||
| 108 | Allograft Rejection | |||
| 109 | Extrinsic Pathway for Apoptosis | |||
| 110 | Focal Adhesion | |||
| 111 | Nifedipine Activity | |||
| 112 | Cardiac Progenitor Differentiation | |||
| 113 | Signaling by VEGF | |||
| 114 | Angiogenesis | |||
| 115 | Fatty Acid Biosynthesis | |||
| 116 | Liver X Receptor Pathway | |||
| 117 | Activation of Gene Expression by SREBP (SREBF) | |||
| 118 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
| 119 | SREBP signalling | |||
| 120 | Metabolism of water-soluble vitamins and cofactors | |||
| 121 | Integration of energy metabolism | |||
| 122 | Fatty acid, triacylglycerol, and ketone body metabolism | |||
| 123 | Vitamin A and Carotenoid Metabolism | |||
| 124 | EGF/EGFR Signaling Pathway | |||
| 125 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 126 | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| 127 | Nanoparticle-mediated activation of receptor signaling | |||
| 128 | EBV LMP1 signaling | |||
| 129 | B Cell Receptor Signaling Pathway | |||
| 130 | Endothelin Pathways | |||
| 131 | Opioid Signalling | |||
| 132 | Integrin-mediated Cell Adhesion | |||
| 133 | Heart Development | |||
| 134 | Type II diabetes mellitus | |||
| 135 | Physiological and Pathological Hypertrophy of the Heart | |||